Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140


Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC, Mangelsdorf DJ, Kliewer SA, Wan Y.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3143-8. doi: 10.1073/pnas.1200797109. Epub 2012 Feb 6.


Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA.

Cell. 2012 Feb 3;148(3):556-67. doi: 10.1016/j.cell.2011.11.062.


Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.

Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M, Véniant MM, Xu J.

Endocrinology. 2012 Jan;153(1):69-80. doi: 10.1210/en.2010-1262. Epub 2011 Nov 8.


The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.

Zweers SJ, Booij KA, Komuta M, Roskams T, Gouma DJ, Jansen PL, Schaap FG.

Hepatology. 2012 Feb;55(2):575-83. doi: 10.1002/hep.24702. Epub 2011 Dec 19.


Time-imposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice.

Oishi K, Konishi M, Murata Y, Itoh N.

Biochem Biophys Res Commun. 2011 Aug 26;412(2):396-400. doi: 10.1016/j.bbrc.2011.07.125. Epub 2011 Aug 3.


Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor?

Uebanso T, Taketani Y, Yamamoto H, Amo K, Ominami H, Arai H, Takei Y, Masuda M, Tanimura A, Harada N, Yamanaka-Okumura H, Takeda E.

PLoS One. 2011;6(8):e22976. doi: 10.1371/journal.pone.0022976. Epub 2011 Aug 1.


Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo.

Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, Kharitonenkov A, Spiegelman BM, Maratos-Flier E.

Endocrinology. 2011 Aug;152(8):2996-3004. doi: 10.1210/en.2011-0281. Epub 2011 Jun 28.


FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway.

Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN, Burgess SC, Mangelsdorf DJ, Kliewer SA.

Cell Metab. 2011 Jun 8;13(6):729-38. doi: 10.1016/j.cmet.2011.03.019.


Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently.

Li X, Fan X, Ren F, Zhang Y, Shen C, Ren G, Sun J, Zhang N, Wang W, Ning G, Yang J.

Diabetes Res Clin Pract. 2011 Jul;93(1):10-6. doi: 10.1016/j.diabres.2011.02.034. Epub 2011 May 18.


Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.

Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, Drápalová J, Hanušová V, Haluzík M.

Physiol Res. 2011;60(4):627-36. Epub 2011 May 16.


FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.

Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, Peterson AS, Sonoda J.

PLoS One. 2011 Mar 18;6(3):e17868. doi: 10.1371/journal.pone.0017868.


FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.

Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ.

Science. 2011 Mar 25;331(6024):1621-4. doi: 10.1126/science.1198363.


Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, French DM, Finn RS, Lowe SW, Powers S.

Cancer Cell. 2011 Mar 8;19(3):347-58. doi: 10.1016/j.ccr.2011.01.040.


A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea.

Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, McKinzie S, Rao AS, Zinsmeister AR, Gores GJ.

Gastroenterology. 2011 Jun;140(7):1934-42. doi: 10.1053/j.gastro.2011.02.063. Epub 2011 Mar 9.


Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21.

Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG.

Mol Med. 2011;17(7-8):736-40. doi: 10.2119/molmed.2011.00075. Epub 2011 Feb 25.


Thermogenic activation induces FGF21 expression and release in brown adipose tissue.

Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, Villarroya F.

J Biol Chem. 2011 Apr 15;286(15):12983-90. doi: 10.1074/jbc.M110.215889. Epub 2011 Feb 13.


Fgf15-mediated control of neurogenic and proneural gene expression regulates dorsal midbrain neurogenesis.

Fischer T, Faus-Kessler T, Welzl G, Simeone A, Wurst W, Prakash N.

Dev Biol. 2011 Feb 15;350(2):496-510. doi: 10.1016/j.ydbio.2010.12.017. Epub 2010 Dec 21.


Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism.

Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, Kuipers F, Murphy EJ.

Hepatology. 2010 Oct;52(4):1455-64. doi: 10.1002/hep.23831.


Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.

Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E.

Diabetes. 2010 Nov;59(11):2781-9. doi: 10.2337/db10-0193. Epub 2010 Aug 3.


Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.

Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W.

J Hepatol. 2010 Nov;53(5):934-40. doi: 10.1016/j.jhep.2010.05.018. Epub 2010 Jul 17.


Supplemental Content

Support Center